Are melanocortin peptides future therapeutics for cutaneous wound healing?

Abstract

Cutaneous wound healing is a complex process divided into different phases, i. e. an inflammatory, proliferative and remodelling phase. During these phases a variety of resident skin cell types but also cells of the immune system orchestrate the healing process. In the last year it has been shown that the majority of cutaneous cell types express the melanocortin 1 receptor (MC1R) that binds α‐melanocyte‐stimulating hormone (α‐MSH) with high affinity and elicits pleiotropic biological effects, e. g. modulation of inflammation and immune responses, cytoprotection, antioxidative defence, and collagen turnover. Truncated α‐MSH peptides such as Lys‐Pro‐Val (KPV) as well as derivatives like Lys‐d‐Pro‐Thr (KdPT), the latter containing the amino acid sequence 193‐195 of interleukin‐1β, have been found to possess anti‐inflammatory effects but to lack the pigment‐inducing activity of α‐MSH. We propose here that such peptides are promising future candidates for the treatment of cutaneous wounds and skin ulcers. Experimental approaches in silico, in vitro, ex vivo and in animal models are outlined. This is followed by an unbiased discussion of the pro and contra arguments of such peptides as future candidates for the therapeutic management of cutaneous wounds and a review of the so‐far available data on melanocortin peptides and derivatives in wound healing.

This article is protected by copyright. All rights reserved.

http://bit.ly/2CwZRxl